Edesa Triples Executive Pay: CEO Salary to $657,423, CFO to $525,938
EDSA has more than doubled off its 52-week low of $0.72 on light trading volume (0.3× avg).
Summary
Edesa's board raised the CEO, President and CFO base salaries to $657,423, $591,681 and $525,938 respectively, retroactive to July 1, 2026 — a large cash commitment for a company that has warned it cannot fund operations through fiscal 2026.
Key Events · Executive and Board Changes · EDSA
-
Executive Base Salaries Roughly Doubled
CEO Pardeep Nijhawan goes from $357,696 to $657,423, President Michael Brooks from $335,340 to $591,681, and CFO Peter Weiler from $300,000 to $525,938, approved by the board on October 23, 2026.
-
Retroactive to July 1, 2026
The increases apply retroactively to July 1, 2026, and follow a pay freeze — the filing states executive base salaries were last adjusted in 2023.
-
Cash Cost Against Going-Concern Warning
The raises add recurring cash compensation at a company whose August 10-Q stated current resources will not fund operations through fiscal 2026.
-
CEO Pay Partly in Stock
90% of Nijhawan's monthly base salary otherwise payable in cash continues to be issued as fully vested restricted share units under the 2019 Equity Incentive Compensation Plan.
Analysis · EDSA · Life Sciences
Why it matters: the board roughly doubled base pay for all three named executives, retroactive to July 1, 2026, after salaries had been frozen since 2023. That is a real cash cost layered onto a company that disclosed in its August 10-Q that current resources will not fund operations through fiscal 2026, so the raises compete directly with trial spending for scarce capital. The optics are also awkward: management is being paid substantially more while shareholders were diluted in the $25 million August offering at $5.50 per share, and the stock now trades at $2.77. Under Nijhawan's arrangement, 90% of monthly salary is paid in fully vested RSUs, which limits actual cash outlay for the CEO but adds share issuance over time.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.2% of the 1549 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EDSA was trading at $2.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.4M. The 52-week trading range was $0.72 to $20.32. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.